MCRB240920C1500
- 0.04
- +0.02+100.00%
Seres Therapeutics Newsroom
Canaccord Genuity Maintains Buy on Seres Therapeutics, Maintains $10 Price Target
Seres Therapeutics Analyst Ratings
Oppenheimer Maintains Seres Therapeutics(MCRB.US) With Hold Rating
Oppenheimer Sticks to Their Hold Rating for Seres Therapeutics (MCRB)
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $10
Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (MCRB), BioMarin Pharmaceutical (BMRN) and Exact Sciences (EXAS)
Chardan Capital Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $1.25
Buy Rating Affirmed for Seres Therapeutics' SER-155 Amid Anticipated Positive Impact on Infection and GvHD Rates
TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating
Oppenheimer Maintains Seres Therapeutics(MCRB.US) With Hold Rating
Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity
Seres Therapeutics (MCRB) Gets a Hold From Oppenheimer
Buy Rating on Seres Therapeutics: Strategic Growth and Promising Clinical Trials Fuel Analyst Confidence
Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target
Chardan Capital Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $1.25
TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating
Strong Sales and Promising Trials Underpin Buy Rating for Seres Therapeutics
Seres Therapeutics Analyst Ratings
Canaccord Genuity Maintains Buy on Seres Therapeutics, Lowers Price Target to $10
Oppenheimer Downgrades Seres Therapeutics to Perform From Outperform, Removes $4 Price Target